Investment Rating - The investment rating for the company is "Buy" (maintained) [1][9] Core Views - The company has demonstrated steady growth in revenue and profit, with a robust expansion in its core property management scale. The operating cash flow has improved, and the gross margin remains stable. The earnings forecast for the years 2025-2027 is projected at 3.8 billion, 4.4 billion, and 5.1 billion respectively, corresponding to EPS of 0.27, 0.31, and 0.36, with current stock price reflecting a PE ratio of 10.6, 9.1, and 7.8 [5][6][8] Financial Performance - For the first half of 2025, the company reported operating revenue of 1.823 billion, a year-on-year increase of 13.35%. The net profit attributable to the parent company was 216 million, also up by 13.23%. The gross margin and net margin were 25.16% and 12.14%, respectively, showing stability compared to the previous year [6][7] - The company’s property management service revenue reached 1.058 billion, growing by 23.1%, while community value-added and collaborative service revenue was 446 million, up by 23.5%. However, non-owner value-added service revenue decreased by 19.4% [7] Business Structure and Growth - As of the end of the first half of 2025, the company had a contracted building area of 113 million square meters and 730 contracted projects, reflecting growth of approximately 3.4% and 3.8% compared to the end of 2024. The managed building area reached 83 million square meters, with 558 managed projects, marking increases of 10.2% and 5.9% respectively [7]

Investment Rating - The investment rating for Poly Property (06049.HK) is "Buy" (maintained) [1] Core Views - The report indicates that Poly Property has achieved steady revenue and profit growth, with a continuous optimization of its value-added business layout. The company is expected to maintain its profit forecasts, with projected net profits for 2025-2027 being 1.58 billion, 1.72 billion, and 1.88 billion yuan respectively, corresponding to EPS of 2.86, 3.11, and 3.40 yuan. The current stock price corresponds to PE ratios of 11.9, 11.0, and 10.0 times [5][6] Financial Performance Summary - For the first half of 2025, the company reported revenue of 8.392 billion yuan, a year-on-year increase of 6.6%, and a net profit attributable to shareholders of 891 million yuan, up 5.3% year-on-year. The gross margin and net margin were 19.4% and 10.8%, respectively, reflecting a decrease of 1.1 percentage points and 0.1 percentage points year-on-year [6] - The company had cash and bank balances of 11.62 billion yuan, an increase of 9.6% year-on-year, and trade receivables of 3.93 billion yuan, up 9.7% year-on-year. The asset-liability ratio decreased by 0.9 percentage points to 42.9% [6] Property Management Revenue Growth - In the first half of 2025, the company expanded its managed scale, achieving property management revenue of 6.325 billion yuan, a year-on-year increase of 13.1%, with the revenue proportion rising by 4.4 percentage points to 75.4%. The gross margin for property management was 16.6%, down 0.2 percentage points year-on-year [7] - The company added 14.06 billion yuan in new third-party projects, a year-on-year increase of 17.2%, with a focus on high-tier cities. The average property management fee per residential unit increased by 0.14 yuan to 2.47 yuan per square meter per month [7] Value-Added Business Adjustments - The company reported a decline in non-owner value-added service revenue to 863 million yuan, down 16.1% year-on-year, primarily due to a decrease in the number of case collaboration service projects and office leasing income. The gross margin for this segment fell by 6.8 percentage points to 11.2% [8] - Owner value-added service revenue was 1.204 billion yuan, down 3.7% year-on-year, but the gross margin improved by 1.1 percentage points to 39.9% [8] Financial Summary and Valuation Metrics - The financial summary indicates projected revenues of 17.731 billion yuan for 2025, with a year-on-year growth of 8.5%. The net profit for 2025 is projected at 1.582 billion yuan, reflecting a year-on-year increase of 7.4% [9]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 91.10, up from a previous target of HKD 87.02 [5][4]. Core Views - The company's revenue for 1H25 reached USD 161 million, representing a year-on-year increase of 33.1%, while net profit surged by 583.6% to USD 14 million. Adjusted net profit also increased by 84.8% to USD 20 million, aligning with prior profit forecasts [1]. - The growth in profit is attributed to robust case growth in the domestic market and sustained high growth in overseas revenue. The delay in the investment in new overseas factories resulted in lower operational costs for 1H25, highlighting the potential for overseas business performance without additional factory investments [1]. - Looking ahead to 2H25, the company expects stable net profit figures due to ongoing case growth domestically and internationally, despite uncertainties in the domestic market and increased costs related to overseas supply chain development and patent improvements [1]. Domestic Business Summary - In 1H25, the domestic market generated USD 90 million in revenue, remaining stable compared to 1H24. The case volume grew by 14% year-on-year to approximately 95,300 cases [2]. - For the full year of 2025, the company anticipates domestic case volume to reach 250,000 cases, driven by the demand for children's orthodontics and product upgrades for adult patients [2]. Overseas Business Summary - The overseas market achieved USD 72 million in revenue for 1H25, marking a 123% year-on-year increase, with case volume rising by 103.5% to 117,200 cases [3]. - The company expects continued high growth in overseas case volume, potentially reaching 240,000 to 250,000 cases for the year, supported by improved product recognition and local sales support structures [3]. Profit Forecast and Valuation - The adjusted EPS forecast for 2025, 2026, and 2027 is USD 0.16, USD 0.16, and USD 0.21 respectively. The company is assigned a 73x PE for 2025, reflecting a premium over comparable companies due to its unique market position and growth potential [4][5]. - The target price of HKD 91.10 reflects the company's growth trajectory and market conditions, with a significant upside from the current closing price of HKD 68.10 [5].

Investment Rating - The investment rating for Huabao International is "Buy" (maintained) [5][9] Core Views - The company has launched an equity incentive plan to strengthen confidence and is looking forward to opportunities in the HNB supply chain [1] - The company reported a revenue of 1.621 billion yuan for the first half of 2025, with a year-on-year growth of 2.5%, and a significant increase in net profit attributable to shareholders by 298% [1][5] - The company aims to accelerate international development and expand overseas markets, with potential merger and acquisition opportunities [4] Summary by Sections Equity Incentive Plan and H1 2025 Performance - The equity incentive plan includes 148 million stock options, accounting for 4.6% of the current total share capital, with an exercise price of HK$3.95 per share [1] - The performance for H1 2025 shows a revenue of 1.621 billion yuan, a gross margin of 43.4%, and a net profit attributable to shareholders of 118 million yuan [1] Downstream Demand - Tobacco production in H1 2025 reached 27.51 million boxes, showing a year-on-year increase of 0.8% [2] - The food and beverage sector saw a year-on-year increase in added value of 7.5% for agricultural and sideline food processing, and 6.3% for food manufacturing [2] Business Segmentation - Revenue from flavor and food ingredients was 596 million yuan, down 8.6%, while revenue from tobacco raw materials increased by 45.3% to 238 million yuan [3] - The company has completed the construction of a new tobacco leaf production base in Indonesia, with an annual capacity of 3,000 tons [3] Outlook for H2 2025 - The company plans to continue accelerating its international development and enhance supply chain management, with cash and financial assets totaling 6 billion yuan as of H1 2025 [4] Financial Forecast - Revenue projections for 2025-2027 are 3.598 billion yuan, 4.075 billion yuan, and 4.670 billion yuan, with year-on-year growth rates of 6.66%, 13.26%, and 14.60% respectively [5][10]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [13]. Core Views - The company is a leading player in China's soft drink industry, effectively driving price inflation in the beverage sector through high-quality, high-priced products, thereby creating substantial profits for upstream suppliers and distributors [4]. - The company has shown resilience in overcoming negative public sentiment and is expected to gradually increase its market share and influence [4]. - The company has established a dual-engine development strategy focusing on packaged water and beverages, leading to rapid revenue and profit growth from 17.5 billion RMB in 2017 to 42.7 billion RMB in 2023, with a CAGR of 16% for revenue and 24% for net profit [7][18]. Summary by Sections Industry Layout - The company has strategically positioned itself in the health-oriented beverage market, launching natural water during the pure water era and sugar-free tea during the sugar tea trend, effectively extending its industrial chain [8]. - It has invested in 15 water sources nationwide, reducing transportation costs and enhancing supply chain stability by supporting local farmers [8]. Product Marketing - The company prioritizes quality in its marketing strategy, avoiding price wars and focusing on premium positioning, which has led to significant growth in its sugar-free tea brand "Oriental Leaf" [9]. - Effective advertising and event marketing have strengthened brand recognition, with slogans like "Nongfu Spring is a bit sweet" resonating with consumers [9]. Channel Management - The company has evolved its distribution model from joint ventures to exclusive distributors, ensuring profitability for distributors and enhancing loyalty [10]. - It employs a dual-channel strategy, focusing on large distributors while supporting smaller ones, which has improved overall channel efficiency [10]. Future Outlook - Despite facing challenges in 2024 due to public relations issues, the company is actively engaging in market recovery efforts and is expected to regain market share by 2025 [11]. - Revenue projections for 2025, 2026, and 2027 are estimated at 49.8 billion RMB, 55.7 billion RMB, and 61.2 billion RMB, respectively, with corresponding net profits of 14.5 billion RMB, 16.6 billion RMB, and 18.6 billion RMB [11].

证券研究报告 医药生物 | 化学制药 港股|公司点评报告 hyzqdatemark 2025 年 08 月 26 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 联系人 市场表现： | 基本数据 | 2025 | 年 | | 日 | 月 | 25 | | 08 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 8.36 | | | | | | 一年内最高/最低（港 | | | 8.40/2.67 | | | | | | | 元） | | | | | | | | | | 总市值（百万港元） | | | | | | | 156,839.60 | | | 流通市值（百万港元） | | | | | | | 156,839.60 | | | 资产负债率（%） | | | | 38.88 | | | | | | 资料来源：聚源数据 | | | | | | | | | 中国生物制药(01177.HK) 投资评级： 买入（维持） ——创新业务加速，BD 出海在 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The report highlights significant improvements in beer cost management, leading to stable profit growth. The company achieved a revenue of 239.42 billion RMB in the first half of 2025, a year-on-year increase of 0.83%, with a net profit attributable to shareholders of 57.89 billion RMB, up 23.04% year-on-year [1][2] Summary by Sections Beer Business Performance - In H1 2025, the company reported beer revenue of 240.75 billion RMB, a year-on-year increase of 6.69%, with sales volume reaching 6.487 million kiloliters, up 2.19% year-on-year. The high-end product segment showed steady growth, with revenue per kiloliter increasing by 4.4% year-on-year. Notably, sales of premium and above beers grew by over 10%, Heineken sales surged by over 20%, and sales of Snow Beer increased by over 70% [2] - Regional performance showed that the East region generated 112.92 billion RMB in revenue, up 3.05% year-on-year; the Central region achieved 66.27 billion RMB, up 2.11%; and the South region reached 61.56 billion RMB, up 1.95% [2] Cost Management and Profitability - The company experienced continuous cost improvements, with a gross margin of 48.88%, an increase of 1.97 percentage points year-on-year. The beer business gross margin rose by 2.50 percentage points to 48.3%. The overall selling expense ratio decreased by 2.03 percentage points to 15.62% [2] - The EBITDA for the beer business in H1 2025 was 72.41 billion RMB, reflecting a year-on-year increase of 13.76%, with an EBITDA margin of 30.08%, up 1.87 percentage points year-on-year. Excluding one-time impacts, the EBITDA margin would have been 31.08% [2] White Spirit Business Performance - The white spirit segment faced challenges, with revenue declining to 7.83 billion RMB, down 33.53% year-on-year, primarily due to reduced business banquet demand. The segment reported an EBITDA loss of 1.52 billion RMB [2] Earnings Forecast and Dividend Policy - The report forecasts earnings per share (EPS) for 2025, 2026, and 2027 to be 1.93 RMB, 1.97 RMB, and 2.09 RMB, respectively. The corresponding price-to-earnings ratios are projected to be 14, 13, and 13 times based on the closing price of 26.29 RMB per share on August 25, 2025. The company plans to maintain a dividend of 0.464 RMB per share, with a payout ratio of 26.07%, reflecting a year-on-year increase of 0.34 percentage points [2][3]

买入（维持） | 市场数据： | 2025 年 08 月 25 日 | | --- | --- | | 收盘价（港币） | 5.85 | | 恒生中国企业指数 | 9248 | | 52 周最高/最低（港币） | 7.19/4.18 | | H 股市值（亿港币） | 192.11 | | 流通 H 股（百万股） | 3,283.96 | | 汇率（人民币/港币） | 1.0981 | 2025 年 08 月 26 日 中海物业 (02669) ——业绩小幅增长，分红率提升 报告原因：有业绩公布需要点评 上 市 公 司 房地产 财务数据及盈利预测 一年内股价与基准指数对比走势： 资料来源：Bloomberg 证券分析师 袁豪 A0230520120001 yuanhao@swsresearch.com 陈鹏 A0230521110002 chenpeng@swsresearch.com 联系人 陈鹏 (8621)23297818× chenpeng@swsresearch.com -5% 45% 95% 08/26 09/26 10/26 11/26 12/26 01/26 02/26 03/26 04/26 ...

Investment Rating - The report maintains a "Buy" rating for the company 德琪医药 (6996 HK) with a target price of HKD 8.80, indicating a potential upside of 38.3% from the current price of HKD 6.36 [6][12]. Core Insights - The latest data on CLDN18.2 ADC confirms its superior efficacy and safety profile compared to potential competitors, leading to an upward revision of long-term sales forecasts and a positive outlook on the company's business development (BD) prospects [2][6]. - The differentiated second-generation TCE platform is significantly undervalued, with promising product and collaboration opportunities anticipated [2][6]. - The company is expected to achieve peak sales exceeding USD 5 billion globally, supported by ongoing clinical developments and regulatory approvals [6][7]. Financial Forecasts - Revenue projections for 2025E, 2026E, and 2027E are set at RMB 123 million, RMB 157 million, and RMB 253 million respectively, with significant growth anticipated in subsequent years [5][13]. - Gross profit margins are expected to remain high, with a gross margin of 81.9% in 2025E, slightly declining to 84.9% by 2027E [5][15]. - The company is projected to incur net losses of RMB 210 million in 2025E, narrowing to RMB 173 million by 2027E [5][13]. Market Performance - The stock has shown remarkable performance with a year-to-date change of 878.46%, reflecting strong investor interest and market confidence [4][12]. - The 52-week high and low for the stock are HKD 7.28 and HKD 0.54 respectively, indicating significant volatility and growth potential [4][12]. Clinical Development - The company has received breakthrough therapy designation for its CLDN18.2 ADC ATG022 for the treatment of CLDN18.2 positive, HER2 negative gastric cancer, with promising clinical trial results showing an overall response rate (ORR) of 40% in high-expression groups [6][7]. - Future development plans include various clinical trials aimed at expanding the indications and enhancing the product's market presence [6][7].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5]. Core Insights - The company achieved a revenue of $16.14 million in H1 2025, representing a year-on-year growth of 33.1%. Net profit reached $1.42 million, up 583.6%, while adjusted net profit was $1.95 million, growing by 84.8% [2]. - The rapid growth of overseas business has become a core driver, with revenue from global markets outside mainland China reaching $7.1 million, a 123% increase year-on-year. Domestic revenue slightly increased to $8.97 million. The total case count for H1 2025 was 225,800, up 47.7% [3]. - The company is focusing on enhancing R&D capabilities, increasing investments in IT, legal, and operational teams, optimizing legal services, expanding production capacity, and broadening its sales network to strengthen its global market presence [4]. Financial Performance Summary - The company forecasts net profits for 2025-2027 to be $1.2 million, $1.9 million, and $2.4 million, respectively, with growth rates of 1.85%, 53.03%, and 27.37%. The expected EPS for the same period is $0.072, $0.111, and $0.141, with corresponding P/E ratios of 133, 87, and 68 [5][9].